StockData
MDXGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

MIMEDX GROUP, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$4.38−0.05 (-1.13%)

Close on Oct 19, 2026

Market cap
$647.35M
P/E (TTM)
109.5
Dividend yield
–

MIMEDX GROUP, INC. revenue by segment

By business segment

RevenueFY2025FY2024FY2023FY2022FY2021FY2020FY2016FY2015FY2014% of revenueYoY
Regenerative Medicine–––$0$16.60M$32.36M–––––
Wound & Surgical–––$264.91M$238.94M$213.49M–––––

By product or service

RevenueFY2025FY2024FY2023FY2022FY2021FY2020FY2016FY2015FY2014% of revenueYoY
Wound$276.33M$231.00M$205.66M$175.97M–––––66.0%+19.6%
Surgical$142.30M$117.88M$115.82M$91.87M–––––34.0%+20.7%
Wound Care––––––$183.98M$141.10M$93.62M––
Surgical, Sports Medicine & Orthopedics (SSO)––––––$61.03M$46.20M$24.60M––
Advanced Wound Care–––$265.20M$240.02M$208.64M–––––
Section 351–––$2.38M$17.61M$31.83M–––––
Tissue/Other–––$241.99M$216.42M$192.57M–––––
Cord–––$23.21M$23.60M$16.07M–––––
Other–––$259.00K$988.00K$7.77M–––––
Hospital–$187.44M$187.00M$163.21M$142.14M$144.29M–––––
Private Office–$112.39M$95.79M$77.16M$74.52M$75.64M–––––
Other–$49.05M$38.69M$27.48M$25.36M$28.31M–––––

By region

From the segment and revenue-disaggregation notes of Mimedx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.